[Targets and possible therapeutic interventions for HIV carriers].
Kageyama
S
S
Department of Pathology, Osaka University.
Kurimura
T
T
D002353:Carrier State / Q000628:therapy*; D004254:DNA Nucleotidyltransferases / Q000627:therapeutic use; D015694:Gene Products, rev / Q000627:therapeutic use; D015696:Gene Products, tat / Q000627:therapeutic use; D005815:Genetic Code; D016679:Genome, Viral; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000628:therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D019426:Integrases; D016337:RNA, Catalytic / Q000627:therapeutic use; D016914:Ribonuclease H / Q000627:therapeutic use; D054321:rev Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus
D015694:Gene Products, rev; D015696:Gene Products, tat; D017320:HIV Protease Inhibitors; D016337:RNA, Catalytic; D054321:rev Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus; D004254:DNA Nucleotidyltransferases; D019426:Integrases; D016914:Ribonuclease H